Unicycive Therapeutics to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference

Core Insights - Unicycive Therapeutics, Inc. is participating in the Guggenheim 2nd Annual Healthcare Innovation Conference on November 10, 2025, where CEO Shalabh Gupta will engage in a fireside chat [1] - The company is focused on developing therapies for kidney diseases, with its lead investigational treatment, oxylanthanum carbonate, currently under FDA review for hyperphosphatemia in chronic kidney disease patients on dialysis [3] - Unicycive's second investigational treatment, UNI-494, is aimed at treating conditions related to acute kidney injury and has received orphan drug designation from the FDA for preventing Delayed Graft Function in kidney transplant patients [3] Company Overview - Unicycive Therapeutics is a clinical-stage biotechnology company specializing in novel treatments for kidney diseases [3] - The company is developing oxylanthanum carbonate as a phosphate binding agent and has completed a Phase 1 safety study for UNI-494 [3] - More information about the company can be found on its website and social media platforms [3]